{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:58:50Z","timestamp":1769155130792,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017-SGR288"],"award-info":[{"award-number":["2017-SGR288"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004812","name":"Gutenberg Forschungskolleg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.leukres.2022.106836","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T19:55:24Z","timestamp":1648324524000},"page":"106836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic\/myeloproliferative neoplasms criteria"],"prefix":"10.1016","volume":"116","author":[{"given":"A.","family":"Triguero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Calabuig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Arzuaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Talarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Coll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Borr\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Marchante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00f3pez-Cadenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Calbacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Simiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MT.","family":"Cedena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pedre\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pedr\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stoica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JM.","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2022.106836_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CCO.0000000000000486","article-title":"Current management of patients with chronic myelomonocytic leukemia","volume":"30","author":"Mora","year":"2018","journal-title":"Curr. Opin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106836_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.leukres.2022.106836_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","article-title":"How I treat chronic myelomonocytic leukemia","volume":"130","author":"Solary","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106836_bib4","unstructured":"Swerdlow SH, Campo E., Harris NL, Jaffe ES, Pileri SA, Stein HTJ. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised Fourth Edition. 4th ed. IARC, editor. 2017."},{"issue":"2","key":"10.1016\/j.leukres.2022.106836_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.leukres.2022.106836_bib6","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring System for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2022.106836_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2022.106836_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2022.106836_bib9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patietnts with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106836_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2022.106836_bib11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A multi-center phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"Drummond","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2022.106836_bib12","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2022.106836_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/hon.986","article-title":"Azacitidine has limited activity in \u2018real life\u2019 patients with MDS and AML: a single center experience","volume":"30","author":"Ozbalak","year":"2012","journal-title":"Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2022.106836_bib14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review","volume":"36","author":"Thorpe","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2022.106836_bib15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106836_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10428194.2012.719617","article-title":"High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study","volume":"54","author":"Fianchi","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2022.106836_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.leukres.2022.106836_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"Pleyer","year":"2014","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2022.106836_bib19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106836_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08893.x","volume":"155","author":"Van der Helm","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2022.106836_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106836_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2022.106836_bib23","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukemia treated with non-curative therapies: a retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2022.106836_bib24","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An International consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106836_bib25","article-title":"Validation of response assessment according to international consortium for MDS\/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood","volume":"7","author":"Duchmann","year":"2017","journal-title":"Cancer J."},{"issue":"33","key":"10.1016\/j.leukres.2022.106836_bib26","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106836_bib27","article-title":"Contemporary treatment approaches to CMML \u2013 is allogeneic HCT the only cure?","volume":"33","author":"Robin","year":"2020","journal-title":"Best. Pr. Res Clin. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106836_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2022.106836_bib29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk. Res"},{"issue":"14","key":"10.1016\/j.leukres.2022.106836_bib30","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:03Z","timestamp":1758934923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":30,"alternative-id":["S0145212622000625"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106836","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic\/myeloproliferative neoplasms criteria","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106836"}}